

# Report to Our Community 2024





# Our Year in Numbers

\$1 Million+

Grants & Fellowships

2,900+

Myotonic Dystrophy Family Registry participants

2,700+

Letters to Congress

2,500+

Support Program participants

737

Regional Conference attendees

11

New publications and translations

# Community, Care and a Cure.

#### Dear Myotonic Dystrophy Foundation Family,

As we look back on 2024, we are filled with immense pride and hope, reflecting on the remarkable strides we've made toward our shared vision of Community, Care, and a Cure for myotonic dystrophy (DM). This year, thanks to our generous donor community, we reached an incredible milestone with over \$1,000,000 invested in research grants and fellowships, including our first-ever short-term high-priority grants and a new pilot grant program, accelerating critical advancements in the search for a cure. With nine drugs currently in clinical trials, we are closer than ever to the long-awaited approval of the first treatment for DM.

Our advocacy efforts reached new heights, as the DM community sent over 2,700 messages to U.S. Congress through our new Voter Voice platform, demanding greater federal research funding. In support of connecting families to clinical care and research opportunities, we shifted our conference structure to hold six regional conferences across the U.S., engaging over 730 individuals. Our support programming flourished as well, with our multilingual Support Groups and Facilitators offering over 230 meetings, providing a safe space for more than 2,500 participants to share, learn, and grow together.

We developed 11 new topic-based resources to further educate and empower our families, and in July we launched Myotonic Dystrophy In Motion Awareness Month to inspire community members around the world to prioritize exercise and wellness. Together, we are making incredible progress, and with each step, we move closer to a future where myotonic dystrophy no longer has the power to define lives.

With deepest gratitude,

Tanya Stevenson, EdD, MPH Chief Executive Officer

Janya Stevenson

**Jeremy Kelly**Chair, Board of Directors

# Our Vision

We envision a world with **treatments** and a **cure** for **myotonic dystrophy.** 



# Our Values

Community
Collaboration
Empathy
Knowledge
Hope
Urgency



# Our Mission

The mission of the Myotonic Dystrophy Foundation is **Community, Care, and a Cure.** 

- → We support and connect the myotonic dystrophy Community.
- → We provide resources and advocate for Care.
- → We accelerate research toward treatments and a Cure.





Founded in 2007, the Myotonic Dystrophy Foundation (MDF) is the leading global advocacy organization helping patients and families navigate life with myotonic dystrophy (DM). MDF is usually the first resource contacted by newly diagnosed patients, their families, social workers, and clinicians looking for support.

# Community

The Myotonic Dystrophy Foundation supports and connects the myotonic dystrophy community.



# MDF Regional Conferences

For the first time, MDF hosted six Regional Conferences across the United States. These conferences were one-day in-person events to connect local DM communities and provide attendees with the opportunity to connect more easily with local researchers and clinicians. We are grateful to our partners in each location who helped make these conferences possible.

2024 Regional Conference Tour →



### Gainesville, Florida

MARCH 23RD
In partnership
with Center for
NeuroGenetics,
University of Florida

College of Medicine
UNIVERSITY of FLORIDA





# By the Numbers

737

Attendees

24

Iravel scholarships

346

First-time attendees

9

Industry sponsors

93

Sessions

3

Lab tours







### Houston, Texas

MAY 4TH In partnership with Houston Methodist



"Meeting and talking with the researchers, seeing and hearing about the process of their work, and seeing the facility was an incredible experience. It was the most meaningful experience in my life with DM..."

- SEATTLE, WASHINGTON LAB TOUR ATTENDEE



Learn more about our past conferences and watch highlight reels from each conference

www.myotonic.org/ our-annual-conferences







Iowa City, Iowa





Boston, Massachusetts

APRIL 6TH

In partnership with Massachusetts General Hospital









106 Attendees









### Seattle, Washington



MAY 18TH
In partnership with UCLA Health





JUNE 1ST
In partnership with
Seattle Wellstone
Muscular Dystrophy
Specialized Research
Center and University
of Washington

# **Support Programs**

MDF's support programs, led by trained community volunteers, create safe and welcoming spaces to build community, learn, and share.



→ Affected Men's Support Group & Affected Women's Support Group

Both of these groups launched in summer 2024 with a record number of registrations — over 70 community members each!

→ Groupe International de Soutien des Francophones & Maryland Support Group

> Our first French-language Support Group and our Maryland Support Group formed in 2024, with their first meetings in January 2025.





[DM] or who have kids with this disease. When I first was diagnosed there were a lot of people who helped my family through the process and I want to do that for others."

— BARBARA OCHOA, SUPPORT GROUP FACILITATOR

# By the Numbers

2,095

Support Group participants

518 Virtual Hand

DM Virtual Happy Hour participants

238

Support Group meetings 21

23 Support

Support Group Facilitators

Support Groups

4

New Support Groups founded Support Group Languages\*

\*German, French, Spanish, English



For more information about Support Groups:

www.myotonic.org/find-support



Meet our Support Group Facilitators at:

www.myotonic.org/sgfs

### Support Groups and Facilitators



#### **TOPIC-BASED**

Affected Men's Support Group

Jim Dolan, Shaun Moore, and Ryan Vogels

**Affected Women's Support Group** 

Jeannine DeSoi and Haley Martinelli

**DM2 Virtual Support Group** 

Haley Martinelli and Tom McPeek

**DM2 Caregivers Virtual Support Group** 

Kim McPeek

**Caregiver Virtual Support Group** 

Annette Rnjak and Ted Salwin

**Caregivers of Children with CDM** 

Sarah Berman

Telefonische Gesprächsgruppe DM1 / DM2

Anke Klein and Bernhard Rogg

**Groupe International de Soutien des Francophones** 

Sarah Berman, Julie LeBoeuf, and Marie-Claude Sauvé

Grupo de Soporte Virtual en Español de MDF

David Kugler and Araceli Mera

**Juvenile-onset Adult (JOA) Warriors** 

Carolyn Valek and Ann Woodbury

**Juvenile-onset Adult (JOA) Caregivers** 

Kyle Dunson, Peggy Melton, and Ann Woodbury

**Adult Facebook Chat** 

Mindy Kim and Bill Nuttall

**DM Virtual Happy Hour** 

Mindy Kim and Kristen McClintock

#### **GEOGRAPHY-BASED**

#### Atlanta, GA

**Chuck Hunt** 

#### Canada

Alex LeBoeuf and Julie LeBoeuf

#### Chicago, IL

Rob Besecker and Ryan Vogels

#### **Finger Lakes and Upstate New York**

**Emily Jones and Lois Schenk** 

#### Florida

Beth Feigenblatt and Kristen McClintock

#### **Kansas City**

John Cooley and Pat Gibson

#### Maryland

Caroline Easterling and Julian Easterling

#### Michigan

Suzanne Perkins and Scott Virgo

#### **Mountain West Region**

Kay Hayes and Kathie Thorsland

#### **New England**

Jeannine DeSoi and Bill Nuttall

#### **New York City/New Jersey**

Janis Jaffe, Glenda Winson, and Guillermo Zubillaga

#### **North & South Carolina**

Mindy Kim

#### Ohio

Nathan Beucler and Carolyn Valek

#### Portland, OR

Mark Coplin

#### Southern California

Rose Albanese and Barbara Ochoa

#### **Texas**

Peggy M. and Lynn S.

#### Virginia

Jodie Howell and Samantha Welsh

#### **Washington State**

Jonathan Freedman and Cindy Hubert



### **DM In Motion**

Myotonic Dystrophy In Motion (MDIM) Awareness Month is designed to provide community members with opportunities for physical activity, education, and community connection.

- MDF hosted its first MDIM Awareness Month in July 2024.
- Throughout the month, MDF hosted four webinars designed for all activity and comfort levels, which followed weekly themes.
- Events engaged community members in educational and inspirational sessions about the importance of exercise, ways to exercise safely at home, and how to connect with nature and ourselves while moving.
- Our In Motion Buddy System offered a chance for participants to connect and collaborate 1:1 with others in the DM community about their experiences and ideas on exercise and movement.
- MDF created the Exercising with Myotonic Dystrophy Infographic that outlines ideas for finding motivation, monitoring exercise, and adding movement to daily life.

"I was so elated!... We are motivated and will stay on our feet and stay in touch long after MDIM Awareness Month has ended."

 MDIM BUDDY PARTICIPANT ON THEIR BUDDY ASSIGNMENT





Download our Exercising with DM Infographic

www.myotonic.org/exercise-info



Learn about MDIM Awareness Month and view the weekly webinars:

www.myotonic.org/in-motion

#### **WEBINAR SERIES**

#### Week 1: Come As You Are! Stump the Doctor & Community Panel

Burning questions and insightful discussions about exercise and mobility with a knowledgeable panel.

#### Week 2: Little Things Count Exercises for Everyday Life

The importance of a balanced movement practice and simple movements that can enhance your overall well-being.

# Week 3: The Natural World The Benefits of Nature & Breathwork

An exploration of the connection between nature, wellness, and breathwork. The transformative power of mindfulness and breathwork practices to enhance daily movement routines.

# Week 4: Let's Keep It Going! Virtual Zumba Class

An exhilarating Zumba class designed to celebrate the achievements of Myotonic Dystrophy In Motion Awareness Month.

### By the Numbers

430+

Recording views

90

Webinar participants

130

Community participants

32

U.S. States represented

83%

Survey respondents found the sessions valuable


14

Countries represented

# JOA Camp

MDF hosts a free camp experience exclusively for JOAs, adults living with juvenile onset myotonic dystrophy.

- MDF was thrilled to again host our JOA Camp
- quintessential summer experience.
- Outdoor Center, a 170-acre facility located on Lake Bloomington in Hudson, Illinois.



"This was one of the best summers of my life. I made many new friends and memories and connected with old friends. I look forward to going back next summer!"

- CHRISTINE BADE, JOA CAMPER





#### **CAMP ACTIVITIES**

- Canoe, kayak, and paddleboard
- Zipline and giant swing
- Archery practice
- Pontoon boat ride
- Marshmallow roasting
- Singing and dancing
- Feeding goats
- And more!





Learn more about our JOA Camp:

www.myotonic.org/camp-joa

# Care

The Myotonic Dystrophy Foundation provides resources and advocates for care.

For those who are diagnosed with DM, finding access to appropriate care from clinicians and healthcare professionals can be particularly challenging. Medical professionals are often unfamiliar with the disease because they see cases so infrequently, and the complicated and variable nature of the disease makes supporting patients and accessing clear treatment guidelines more difficult.



#### **WARMLINE**

The MDF Warmline connects patients—many newly diagnosed—and their family members with resources, support, and education.

Need Support? Contact us at +1 (415) 800-7777 or info@myotonic.org

# By the Numbers

33,000+

Resource downloads from our website

Videos added to the

MDF Digital Academy

New publications

Warmline calls and email interactions

Languages of MDF resources

and translations

[The Ask-the-DM-Expert webinar provided] a very clear and complete presentation, explanations, and PowerPoint slides. Clear answers to commonly raised questions, provided by a recognized and experienced professional. This was a great presentation and webinar!"

- GENETIC TESTING & COUNSELING FOR DM WEBINAR ATTENDEE





:Buenos días! Visit our Spanish language hub:

www.myotonic.org/espanol



**Guten Tag!** Visit our German language hub:

www.myotonic.org/deutsch

# **Empowering the DM Community through Education**

Access a wealth of materials and resources for individuals, families, and clinicians on the MDF website.



www.myotonic.org/ toolkits-publications

#### FIND-A-DOCTOR MAP

This community-driven map helps affected individuals, families, and caregivers connect with medical professionals who have experience working with DM patients. Visit the map to help find or contribute information about medical professionals in your area. www.myotonic.org/find-a-doctor-map

#### MDF DIGITAL ACADEMY

The largest DM-focused digital library in the world houses more than 200 hours of educational and inspirational videos by DM experts. www.myotonic.org/digital-academy

#### **ASK-THE-DM-EXPERT**

This virtual webinar series features DM clinicians and experts in diverse specialties who give recorded presentations and participate in live Q&A sessions with webinar attendees.

www.myotonic.org/ask-expert-series

#### 2024 Ask-the-DM-Expert Webinars

- DM & the Heart
- Genetic Testing & Counseling for DM
- GI Issues & DM
- Reproductive Health & DM

#### **TOOLKITS & PUBLICATIONS**

MDF resources help guide health care providers and families in the care and management of DM.

#### **New Publications**

- Exercising with Myotonic Dystrophy Infographic (English)
- MDF Medical Alert Card (French-Canadian)
- Myotonic Dystrophy and Mental Health Handbook (English and Spanish)
- Myotonic Dystrophy and the Heart: A Community Guide (English and Spanish)
- Practical Advice for Anesthesia for Individuals with Myotonic Dystrophy and Their Families (English)
- Nutrition Guide (Spanish)
- Role of Physical Therapy (Spanish)

#### **New English Translations**

MDF facilitated translation of two seminal works about myotonic dystrophy from German into English, both originally published more than a century ago.

- Dr. Hans Steinert's initial descriptions of patients with myotonic dystrophy (1908)
- Dr. Bruno Fleischer's "On Myotonic Dystrophy with Cataracts: A Hereditary, Familial Degeneration" (1918)



#### **Understanding DM**

MDF is excited to introduce *Understanding Myotonic Dystrophy*, a series of short educational animations designed to help individuals living with DM and their families better understand the condition.

#### Watch & Learn



www.myotonic.org/understanding-DM

# Cure

The Myotonic Dystrophy Foundation accelerates research toward treatments and a cure.



# Advancements in DM Research

Since its founding in 2007, MDF has helped dramatically change the DM research and drug development landscape.

MDF plays a key role in DM research and drug development by investing in research, researchers, and initiatives to attract more industry, foundation, and government funding. We help researchers, drug companies, and regulators to understand the needs of people living with DM. We also connect individuals with DM to information about research studies and trials.

www.myotonicregistry.org



#### **Myotonic Dystrophy Family Registry (MDFR)**

#### Your Participation Makes a Difference!

Sharing information with the MDFR, through surveys and medical reports, can play a critical role in accelerating progress towards finding effective treatments and a cure.


#### Login now:

www.myotonicregistry.org

#### **Questions?**

Call us at +1 415-800-7777

# **Supporting DM Clinical Studies & Trials**



#### **Myotonic Dystrophy Clinical Research Network (DMCRN)**

MDF expands clinical study and trial infrastructure by contributing funding and support to the DMCRN, a network of more than 20 medical centers in the U.S., Europe, Japan, and New Zealand. www.myotonic.org/dmcrn

#### **Study and Trial Resource Center**

This resource provides details on studies and trials, including the clinical trial process, participant guidelines, and a list of current clinical studies and trials. www.myotonic.org/studytrial-resource-center

#### CONNECTING THE COMMUNITY WITH DM DRUG DEVELOPERS

MDF's "Meet the DM Drug Developers" webinar series, hosted since 2021, connects biotech and pharmaceutical partners with our community to share updates and to answer questions in a live format. The series has had more than 17,000 views since its launch! In 2024, we featured the following partners in the series:













### By the Numbers

2,900+ Participants in the Myotonic Dystrophy Family Registry

#### 25+

DM drugs in clinical pipeline

DM drugs in Phase I/II/III clinical trials

Meet the DM Drug Developers webinars

#### 6

Industry update sessions at Regional Conferences



Learn about different DM drugs in development:

www.myotonic.org/pipeline



Watch or participate in Meet the DM Drug Developers webinars:

www.myotonic.org/meetdm-drug-developers

# MDF Research Investments

MDF is investing in the next generation of DM researchers and thought leaders.

# By the Numbers

### \$1.7 Million

Invested in Research Programs in 2024

\$380,000

for 2 Early Career Scholar Grants

\$220,000

for 4 Doctoral Research Fellowships

\$200,000

for 4 Pilot Grants

\$100,000

For 2 Short-Term High-Priority Grants

56

Number of Research Fellows Funded since 2009

#### \$7 Million+

MDF investment in Research Fellowships & Grants since 2009

#### **Research Fellows Program**

Created in 2009, our flagship program provides two-year pre- and postdoctoral research fellowships to support new and innovative studies relevant to myotonic dystrophy.

#### **Early Career Scholars Program**

This program was launched in 2023 to help retain early career scholars who are passionate about research in the DM field. MDF prioritizes funding clinical researchers and physician-scientists with these two-year grant awards.

#### **Pilot Grant Program**

This new program supports innovative DM research to gather preliminary data on novel ideas.

#### **Short-Term High-Priority Grants**

These grants are awarded to researchers for one-year projects focused on high-priority topics, as identified by MDF's Board of Directors.

#### **Small Grants Program**

Created in response to a need to expand access and boost research efforts in DM, this program provides grants for research journal open access fees (up to \$5,000) and scientific conference presentation and travel expenses (up to \$2,500).



Learn more about MDF's research funding program:

www.myotonic.org/grants





Johanna Hamel, MD

Assistant Professor | University of Rochester, New York, U.S.

Dr. Johanna Hamel's study, "Remote Assessments in Myotonic Dystrophy," explores how the length of the CTG repeat mutation influences the timing and severity of DM1 symptoms. The research uses video conferencing and toolkits to reach diverse participants, aiming to uncover additional genetic factors and improve patient registries for future clinical trials.



#### Tahereh Kamali, PhD

Postdoctoral Research Fellow | Stanford University School of Medicine, California, U.S.

Dr. Tahereh Kamali's study, "Utilizing Generative AI to Expand Clinical Data for DM Studies and Treatment Efficacy Planning," seeks to enhance an AI model she developed that identifies changes in the central nervous system related to DM. By generating synthetic data and using real-world patient data, the project aims to improve diagnosis accuracy and advance personalized treatments for DM patients.

#### 2024 Research Fellows

**\$220,000 INVESTMENT** 



#### **Betty Bekele**

Emory University, Atlanta, Georgia, U.S.

Betty Bekele's study, "Altered Inhibitory Neurotransmission in Mouse Models of Myotonic Dystrophy Type 1," explores how DM1 affects GABA, a brain chemical crucial for sleep and anesthesia sedation. By studying changes in GABAA receptor subunits, the research aims to understand DM1's impact on the brain and test therapies, including flumazenil, to improve sleep and anesthesia-related complications in DM1 patients.



#### Sakura Hamazaki

University of Rochester, New York, U.S.

Sakura Hamazaki's study, "Impact of Calcium Entry through Cav1.1 in Myotonic Dystrophy Myopathy," investigates how altered ion channels, particularly Cav1.1, contribute to muscle weakness in DM1. Using mouse models, the study aims to correct the function of these channels and validate them as therapeutic targets, with potential implications for developing or repurposing treatments for DM1.



#### Alexandra L. Marrero Quinones

Virginia Commonwealth University, Richmond, Virginia, U.S.

Alexandra L. Marrero Quinones' study, "Evaluation of MSH3 as a Genetic Modifier of Trinucleotide Repeat Instability in Myotonic Dystrophy," investigates the role of DNA repair genes, particularly MSH3, in the rapid expansion of CTG repeats in congenital DM1. By analyzing blood samples from families with rapid repeat expansion, the study aims to uncover how MSH3 variants contribute to repeat instability, offering insights into disease progression and potential new therapeutic targets for DM1.



#### **Cameron Niazi**

University of Florida, Gainesville, Florida, U.S.

Cameron Niazi's project, "Leveraging CRISPR/Cas-based Epigenetic Modifications for the Treatment of Myotonic Dystrophy Type 1," explores a novel CRISPR/Cas approach to silence the faulty DM1 gene without cutting the DNA, reducing the risks of off-target effects. By turning off the gene responsible for producing toxic RNA, this project aims to provide a safer alternative to traditional gene editing, offering a promising new therapeutic strategy for DM1.



Joel R. Chamberlain, PhD

Research Associate Professor | University of Washington, Seattle, Washington, U.S.

Dr. Joel Chamberlain is exploring a novel approach to treat DM1 by using natural cell-derived vesicles to deliver drugs that can destroy toxic RNA structures in muscles in her project, "Efficacy Testing of Cell-Derived Nanovesicle Delivery of Small Interfering RNAs for Treatment of DM1." If successful, this could lead to a new, non-invasive treatment that targets the root cause of DM1.



#### Paloma Gonzalez Perez, MD, PhD

Neuromuscular Attending | Massachusetts General Hospital, Boston, Massachusetts, U.S.

In her project, "Investigating Benefits of a Physical Therapist-Guided Exercise Program in Myotonic Dystrophy Type 2," Dr. Paloma Gonzalez Perez is testing the effectiveness of a simple, guided exercise program designed to improve motor function and reduce pain in DM2 patients. Her study will examine the long-term benefits of exercise under physical therapist supervision, with the goal of making this program accessible to more DM2 patients.



#### **Emma Matthews, FRCP**

Reader of Neurology and Consultant Neurologist | St George's, University of London, U.K.

Dr. Emma Matthews aims to uncover why DM1 patients are more prone to abnormal lipid profiles (dyslipidemia) in her project, "Exploring Transcriptional Dysregulation of Lipid Metabolism Genes in DM1." By comparing lipid metabolism genes in DM1 patients with and without dyslipidemia, her study could lead to better treatment guidelines and new therapies for managing this condition.



#### Belinda Pinto, PhD

Research Assistant Scientist | University of Florida, Gainesville, Florida, U.S.

In her project, "Investigating the Contribution of Circadian Disruption to Hypersomnolence in Myotonic Dystrophy," Dr. Belinda Pinto is studying how disruptions in the circadian system contribute to excessive daytime sleepiness in DM1 patients. Using animal models, she seeks to understand the molecular causes of hypersomnia and pave the way for future therapeutic developments.

### Short-Term High-Priority Project Awardees

\$100,000 INVESTMENT



#### Kristina Kelly, DPT

Assistant Research Professor | University of Missouri-Columbia, Missouri, U.S.

Dr. Kristina Kelly's study, "Neural Mechanisms of Motor Fatigability in Myotonic Dystrophy Type 1," explores how the nervous system contributes to motor fatigability in individuals with DM1. By comparing nervous system activity before and after exercise between DM1 patients and healthy controls, the study aims to uncover the biology behind fatigue and develop better strategies for managing it.



#### Lukasz Sznajder, PhD, MSc

Assistant Professor | University of Nevada, Las Vegas, U.S.

Dr. Lukasz J. Sznajder's study, "Delineating Pathogenic RNA Species in Myotonic Dystrophy Type 2," aims to validate the hypothesis that mRNA with retained CCUG repeats plays a central role in DM2's molecular changes. By using DM2-derived cell lines, tissues, and advanced bioinformatics, the study seeks to identify key pathogenic molecules and develop potential preventative therapies, ultimately advancing understanding and treatment of DM2.

# Advocacy

The Myotonic Dystrophy Foundation advocates for improved care and a cure.

# By the Numbers

2,754

Advocacy campaign messages to Congress

1,159

New advocates participated in grassroots campaigns

16

Senators and Representatives signed letter of support for CDMRP funding of DM research

# **Advocacy Initiatives**

MDF drives key initiatives for improved care and accelerated research while raising DM visibility with stakeholders in U.S. Congress and other policymakers, federal and state agencies, regulatory agencies, medical professionals, and the media.

#### **MDF Empowers Grassroots Advocates**

MDF empowered thousands of our community members to engage in grassroots advocacy through a new platform called Voter Voice. Community members who visit our custom webpage can email preloaded advocacy messages to their Senators and Representatives. In 2024, MDF launched three advocacy campaigns with Voter Voice, generating 2,754 messages to Congress.

# Congressionally Directed Medical Research Program (CDMRP) Advocacy

Our 2024 advocacy campaigns urged Congress to increase federal funding for myotonic dystrophy, specifically requesting \$10 million for DM research as part of the Fiscal Year 2025 Congressionally Directed Medical Research Program (CDMRP). Thanks to the support of our grassroots advocates, 16 U.S. Senators and Representatives signed on to letters of support for CDMRP funding. Although Congress did not include DM research in their 2025 Fiscal Year budget, we are proud of the work that we accomplished together and will try again!

#### **State Captain Recruitment**

In December 2024, MDF launched a recruitment campaign to have U.S. State Advocacy Captains in all 50 states. State Advocacy Captains will 1) coordinate meetings with their state congressional delegations several times a year in support of MDF's research advocacy objectives; and 2) recruit and mobilize grassroots advocates in their state to build awareness and secure more federal funding for DM research.







Representative Jen Kiggans (R-VA)

Representative Jared Moskowitz (D-FL)

Honored for leading the first ever congressional letter to the House Appropriations Committee in support of MDF's request for \$10 million in DM research as part of the Congressionally Directed Medical Research Program (CDMRP). It was signed by 11 members of the U.S. House of Representatives and 5 members of the U.S. Senate!



Representative Jen Kiggans (R-VA)



Representative Jared Moskowitz (D-FL)



# PEER REVIEW MEDICAL RESEARCH PROGRAM (PRMRP)

MDF Congressional advocacy secured continued federal research funding eligibility for DM from the Department of Defense's Peer Reviewed Medical Research Program (PRMRP) for the eighth year in a row.

Over the past seven years, PRMRP has allocated over \$23 million to DM research, significantly enhancing our understanding of both DM1 and DM2. PRMRP funding has been instrumental in advancing breakthrough research and therapy development. PRMRP-funded studies have uncovered key insights into DM, leading to promising treatment strategies. Funding has supported research on gene editing and molecular therapies, giving hope to the DM community.



# NATIONAL ADVOCACY COMMITTEE (NAC)

MDF's NAC was founded in 2022 to lead new advocacy campaigns and motivate the DM community to advocate for increased federal research funding. We are grateful to our NAC members for their advocacy leadership!

Rob Besecker Illinois

David Brand\* Virginia

Martha Montag Brown California

Rebecca Coplin Oregon

**Belen Esparis** Pennsylvania Lisa Harvey-Duren\* West Virginia

Charles Hunt Georgia

Emily Jones New York

**Eric Wang** Florida

Leo Zabezhinsky\* Minnesota

\*New in 2025





#### Let your voice be heard!

Learn more about MDF's advocacy initiatives and take action:

www.myotonic.org/advocate

# **International DM Awareness**

The Global Alliance for Myotonic Dystrophy Awareness celebrates International Myotonic Dystrophy Awareness Day on **September 15th**.

- MDF is proud to be a founding member of the Global Alliance for Myotonic Dystrophy Awareness. Established in 2021, the Global Alliance now includes over 60 international nonprofit organizations, academic and research institutions, biotechnology and pharmaceutical companies, patient advocacy groups, and others working together to raise myotonic dystrophy awareness.
- Global Alliance members directed their energies toward two primary areas of focus throughout the year: 1) Awareness and education among clinical care teams, and 2) Clinical trial readiness for participants.
- Partners mobilized to illuminate the DM community by lighting monuments and landmarks green all over the world on **September 15th**. This initiative increased DM visibility across communities and social media.







Myotonic





- → Light up your local landmarks, monuments, and important buildings in green
- → Share the International Myotonic Dystrophy Awareness Day logo
- → Social Media Campaign: During the month of September, post DM facts and your experiences on social media to help people understand more about the disease
- → Window Sign Campaign: Ask neighbors and shops in your community to display an International Myotonic Dystrophy Awareness Day window sign



How will you celebrate on **September 15th?** 

For tips, suggestions, and resources: www.myotonic.org/international-dm-day

# The Global Alliance for **Myotonic Dystrophy Awareness**





Spain

Nemo



Spain



**Maastricht UMC+** 

**Netherlands** 



Netherlands

Europe





Canada

Japan



Denmark



**United Kingdom** 

**United Kingdom** 

**United Kingdom** 

**United Kingdom** 

















**United Kingdom** 





**United Kingdom** 

USA

**USA** 

**USA** 

**USA** 







**USA** 



USA





**USA** 

USA





USA

**USA** 



USA



USA



USA



USA



USA

USA



Paul D. Wellstone Muscular Dystrophy











USA





**USA** 







UNIVERSITY OF IOWA HEALTH CARE







USA





Worldwide

# Fundraising

Our donors make it possible for the Myotonic Dystrophy Foundation to advance our mission of Community, Care, and a Cure.

#### **Changing the Future of Myotonic Dystrophy**

MDF's Change the Future of Myotonic Dystrophy end-of-year fundraising campaign featured a series of four new impactful videos, profiling families affected by DM. We are grateful to all of the individuals who participated in the interviews, with special thanks to Luke Desforges, Ben Reynolds, and Kim Reynolds for sharing your experience living with DM.







Check out our Change the Future of Myotonic Dystrophy video series to learn more about the impact of your support!

www.myotonic.org/impact

# \$ Raised in 2024

\$3.2 Million

**Total Contributions** 

\$1.6 Million

Gala

\$380,000

Corporate Sponsorships

\$70,000

Fundraising campaigns hosted by community members









# DIY Fundraising


Community members raised awareness about DM, and funds for MDF, through a total of 130 different fundraising campaigns, ranging from endurance events and golf tournaments to in-person donation drives and social media fundraisers.

#### Casey & Max's Half-Marathon Challenge

Running a half-marathon had been on Casey and Max Segal's bucket list for years. In spring 2024, they decided to make their dream a reality by signing up for a race on Staten Island, scheduled six months later, and began their training together. With no experience running more than two miles at a time, the challenge ahead was daunting.


When Casey's father passed away unexpectedly in May, their grief fueled their determination to reach their goal. Casey's father had lived with DM, which her 26-year-old brother also inherited. To give their challenge even more significance, Casey and Max turned their half-marathon into a fundraiser for MDF, honoring both her father and brother.

Not only did they complete their first half-marathon, they also raised nearly \$20,000 for MDF. Thank you, Casey and Max, and all of your generous supporters!



"I am so hopeful for the future and what MDF can accomplish with the right funds and team supporting their mission."

CASEY SEGAL. DONOR & DIY FUNDRAISER





#### New Fundraising Platform and Toolkit

MDF created a new DIY fundraising platform and toolkit to empower our community members to create their own unique fundraisers and manage their campaign webpages.



Interested in fundraising for MDF? Learn more here:

www.myotonic.org/diy

# 2024 MDF Gala

Our annual Gala raised a record-setting \$1.6 Million!



#### **GALA HIGHLIGHTS**

- Our 10th annual fundraising Gala was held on September 14th at the Taglyan Complex in Hollywood, California.
- Critical funds raised at the event improve quality of life for individuals and families living with DM and accelerate research towards treatments and a cure.
- We are beyond grateful to our event attendees, sponsors, donors, and volunteers for making the Gala so incredibly successful!
- Thank you to all the families and research partners who shared their stories for our four Gala videos. These compelling videos helped guests better understand the lived experience of DM, offered hope for the future, and inspired people to give generously in support of our mission.









Join us for the 2025 Gala on September 18th in NYC!

www.myotonic.org/gala

### 2024 Gala Committee

Thank you to our 2024 Gala Committee, who organized and executed this successful fundraising event!

Martha Montag Brown Co-Chair

Erica Kelly Co-Chair **Peter Desforges** 

**Suzanne Desforges** 

**Elizabeth Florence** 

**Whitney Gates** 

**Alex Kapp** 

Leslie Lynch

Laurie Rodli


**Benjamin Youngblood** 



# MDF Financials


# \$35 Million+

Amount raised by MDF since 2007 to support its mission of Community, Care, and a Cure



~80% of donations are from individual donors.

\*Based on unaudited financial statements



84% to Research, Care, and Advocacy programs in 2024.

# Mail-in Donation Please make checks payable to

Myotonic Dystrophy Foundation 663 13th Street, Suite 100 Oakland, CA 94612

#### **Online Donation**

One-time and recurring gifts

#### More Ways to Give

- » Stock
- » Donor Advised Funds
- » IRA Qualified Charitable Contributions
- » Workplace & Corporate Matching Gift Programs

#### QUESTIONS?

Call us at +1 415-800-7777

or email development@myotonic.org



Invest in Our

Mission



**Donate Online!** 

www.myotonic.org/donate



# Myotonic Dystrophy at a Glance





Myotonic dystrophy is a rare, multi-systemic, inherited disease that may affect as many as **1** in **2,100** people, or over 3 million individuals across the world.



Myotonic dystrophy is inherited — people living with myotonic dystrophy have a 50% chance of passing on the mutated gene to their children.



Millions of people are living with DM globally, yet millions of people do not know they have the disease and are in need of care.



People living with myotonic dystrophy experience varied and complex symptoms,

from skeletal muscle problems, to heart, breathing, digestive, hormonal, speech and swallowing, diabetic, immune, excessive daytime sleepiness, early cataracts and vision challenges, and cognitive difficulties.



Myotonic dystrophy is the most common form of adult muscular dystrophy and considered the most variable of all known conditions.



Myotonic dystrophy does not always

look the same. The different body systems affected, the severity of symptoms, and the age of onset of those symptoms vary greatly between individuals, even in the same family.



Myotonic dystrophy is commonly referred to as DM, an abbreviation of the Latin name used by doctors and researchers worldwide: dystrophia myotonica. Other names for DM include myotonic muscular dystrophy (MMD), Steinert's Disease for DM1, and proximal myotonic myopathy (PROMM) for DM2.



Delays in diagnosing myotonic dystrophy

**are common.** Despite the availability of simple genetic tests, a lack of familiarity with the disease on the part of healthcare providers can allow misdiagnoses to persist for decades.



Myotonic dystrophy symptoms usually become more severe with each generation, yet there is currently no cure and there are no approved treatments.



Over 40 biopharmaceutical companies are leading promising research which may result in new treatments for myotonic dystrophy, and, one day, a cure.



Mutations prevent genes from carrying out their functions properly, which can impact multiple body systems. Myotonic dystrophy type 1 is caused by a mutation in the DMPK gene, while myotonic dystrophy type 2 is caused by a mutation in the CNBP gene.



Learn more and find citations at:

www.myotonic.org/at-a-glance



Read about MDF's impact at:

www.myotonic.org/impact



663 13th Street, Suite 100 Oakland, CA 94612

**BOARD OF DIRECTORS** 

**Jeremy Kelly**Board Chair & Lifetime Trustee

Martha Montag Brown Vice-Chair

Elizabeth Florence, Esq. Secretary

**David Herbert** *Treasurer* 

Andy Berglund, PhD

David Berman, MBA

Robert Campagna, MD

John W. Day, MD, PhD

Belen Esparis, MD

Haley Martinelli, Esq.

**Thomas McPeek** 

**Charles Thornton, MD** 

SCIENTIFIC ADVISORY COMMITTEE

Andy Berglund, PhD

Scientific Advisory Committee Chair

Guillaume Bassez, MD, PhD

Kathie Bishop, PhD

Thomas A. Cooper, MD

John W. Day, MD, PhD

Cynthia Gagnon, PhD

Nicholas E. Johnson, MD, MSci, FAAN

Douglas Kerr, MD, PhD, MBA

Darren Monckton, PhD

Laura Ranum, PhD

Jacinda Sampson, MD, PhD

**Charles Thornton, MD** 

**Eric Wang, PhD** 

**Tetsuo Ashizawa, MD** (Emeritus Member)

Richard Moxley III, MD (Emeritus Member)

**CONNECT WITH MDF** 

**f** MyotonicStrong

(©) @myotonicstrong

myotonicstrong

myotonicstrong. bsky.social

Phone

+1 415-800-7777

**Email** 

info@myotonic.org

Website

www.myotonic.org

**STAFF & CONSULTANTS** 

Tanya Stevenson, EdD, MPH Chief Executive Officer

Kate Beck

Director of Development (through May 2024)

Kevin Brennan

Advocacy Consultant

Mindy Buchanan

Director of Programs

**Scarlett Chidgey, MA**Director of Development

**Kleed Cumming** 

Director of Communications & Technology

Mindy Kim

Registry Outreach Consultant

**Sofia Olmos, PhD** Registry Coordinator

Andy Rohrwasser, PhD, MBA

Chief Scientific Officer

**Emily Romney** 

Senior Manager of Community Education

Lucie Shiffman

Senior Manager of Community Engagement

Nadine Ann Skinner, PhD, MPA

Director of Evaluation & Research Programs

**Genevieve Wiegleb** 

Communications Associate

**Renee Smith** 

Fundraising & Operations Coordinator

**Elias Trevino** 

Administrative Volunteer